在一次性免疫缺陷中用IgA和IgM丰富的免疫球蛋白:试点研究
Aurore Collet1,2,3, Benjamin Coiffard4, Emmanuel Ledoult5,6,7
1Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, F-59000, France. aurore.collet@chu-lille.fr.
Journal of clinical immunology
|November 28, 2025
概括
患有原发性免疫缺陷 (PID) 和低IgA/IgM水平的患者在接受IgA和IgM (IgGAM) 丰富的免疫球蛋白制剂后,感染和住院病例较少. 这表明IgGAM可能会改善持久性感染的PID患者的临床结果.
科学领域:
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 主要免疫缺陷 (PID) 通常涉及复发性感染.
- 标准免疫球蛋白替代疗法 (IgRT) 可能对一些PID患者不足,特别是那些没有检测到IgA和IgM的患者.
- IgA和IgM对粘膜和补充介导免疫非常重要.
研究的目的:
- 评估IgA和IgM丰富免疫球蛋白制剂 (IgGAM) 的安全性和临床结果,用于患有无法检测IgA/IgM和持久感染的PID患者.
- 评估IgGAM对感染率,住院和生物标志物的影响.
主要方法:
- 法国的一项同情使用计划 (CUP) 招募了20名PID患者.
- 患者每7-14天接受一次静脉注射IgGAM输液.
- 安全性,耐受性,感染频率,住院次数和免疫学标记被前性分析.
主要成果:
- 没有报告严重的不良事件;一半的患者出现轻度过敏.
- 平均抗生素疗程 (5.4至2.3/年) 和住院病例 (2.6至1.2/年) 显著减少.
- 血清IgA和IgM水平增加,在唾液中检测到IgA/IgM,这表明粘膜转移.
结论:
- 在患有无法检测到IgA/IgM的严重PID患者中,IgGAM与减少感染和住院病例有关.
- 需要进一步的受控研究来证实IgA/M丰富免疫球蛋白制剂的益处.
- 对于患有持续或复发性呼吸道或消化道感染的PID患者,IgGAM显示出有前途.
更多相关视频
06:15Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
Published on: September 7, 2018
9.8K
08:25Unraveling Key Players of Humoral Immunity: Advanced and Optimized Lymphocyte Isolation Protocol from Murine Peyer's Patches
Published on: November 21, 2018
14.2K
相关概念视频
01:25Immunodeficiency Diseases
1.9K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
1.9K
01:22Development of Immunocompetence
773
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
773